Analytical Data
-
基因名
NAT2
- Application
-
别名
NAT2；NARG1L；NAT2；N-alpha-acetyltransferase 16. NatA auxiliary subunit
-
种属
Human
-
表达系统
E. coli
-
标签
His tag N-Terminus
-
纯度
Greater than 90% as determined by SDS-PAGE.
-
蛋白编号
P11245
-
表达区间
1-290aa
-
氨基酸序列
MDIEAYFERIGYKNSRNKLDLETLTDILEHQIRAVPFENLNMHCGQAMELGLEAIFDHIVRRNRGGWCLQVNQLLYWALTTIGFQTTMLGGYFYIPPVNKYSTGMVHLLLQVTIDGRNYIVDAGSGSSSQMWQPLELISGKDQPQVPCIFCLTEERGIWYLDQIRREQYITNKEFLNSHLLPKKKHQKIYLFTLEPRTIEDFESMNTYLQTSPTSSFITTSFCSLQTPEGVYCLVGFILTYRKFNYKDNTDLVEFKTLTEEEVEEVLKNIFKISLGRNLVPKPGDGSLTI
-
分子量
49.5kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
NAT2 (N-acetyltransferase 2) is an enzyme involved in the metabolism of various drugs and xenobiotics, playing a crucial role in the biotransformation processes that affect individual drug responses and toxicity. Genetic variations in the NAT2 gene result in distinct phenotypes categorized into fast and slow acetylators, which significantly influence the metabolism of certain medications, including anti-tuberculosis and anti-cancer drugs. Research into NAT2 has garnered attention due to its implications in pharmacogenomics, as understanding these genetic differences can lead to more personalized and effective therapeutic strategies. The study of NAT2 recombinant proteins has facilitated better insights into the enzyme's structure-function relationships, enzymatic activity, and substrate specificity. This research is essential for elucidating the enzyme's role in drug metabolism and the potential associations with adverse drug reactions, cancer susceptibility, and overall health outcomes. By exploring NAT2's biochemical mechanisms, researchers aim to improve drug development processes and optimize clinical treatments tailored to individual patient genotypes.
